Centene’s 19.9% Earnings Estimate Upgrade Powers 34.5% Year-to-Date Gain
CNC•Centene’s earnings consensus rose 19.9% over the past quarter, earning a Zacks Rank #1. Its stock has gained 34.5% year-to-date versus a 6.8% average loss for Medical stocks.
1. Year-to-Date Performance
Centene has gained about 34.5% so far this year, outperforming the Medical sector’s average 6.8% decline in year-to-date returns.
2. Analyst Rankings and Estimate Revisions
Centene holds a top Zacks Rank #1 and saw its full-year earnings consensus climb 19.9% in the past quarter, signaling stronger analyst outlook and earnings momentum.
3. Industry Positioning
Within the Medical – HMOs industry (8 companies), ranked 53rd, Centene’s 34.5% year-to-date return tops the group’s 9.9% average gain to date.
4. Peer Comparison
Cellectar Biosciences has returned 19.7% year-to-date and experienced a 59.3% rise in its EPS consensus over three months while holding a Zacks Rank #2.
